Audit: QRS - Beta-Alanine for Health & Longevity

Audit conducted on 22/09/2026 16:38 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	83
Failed	0
N/A	11
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Verified span by span against the ER: protocol (ER 277–285), time to effect (ER 314), benefits (ER 147–187), risks (ER 206–230), gates (ER 244–260), monitoring table (ER 336–343), qualitative markers (ER 347–352).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious framing preserved: “theoretical additive effect” (marker_3_why), “if it exists” (marker_4_why), “no established clinical target” (marker_8_target), “absence of any confirmatory trial” (qualitative_item_6).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds carried at ER strength (ALT >3× upper reference limit, eGFR <30, Child-Pugh C); no gate softened to “caution”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefit-modifying and risk-modifying factors from ER lines 192–199 and 235–239 are not surfaced in the gates; gates draw only from ER 244–260.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	QRS carries no PMIDs, study citations, expert names, NCT identifiers, or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present; ER attributions (Derave/Ghent, ISSN, CarnoSyn/NAI) are all omitted.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, plain, non-promotional register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven (thresholds, ranges, tiers) while remaining readable.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents tiers, gates and ranges; no prescriptive instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Fixed template disclaimer only; body text describes what trials used rather than directing care.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Descriptive throughout; no “recommend”, “advise”, or “should” in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere in the rendered body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language used throughout; retained technical terms (paresthesia, aquagenic pruritus) are the ER’s own section headings, whose glosses 12.4/13.4 require stripping.
2.8	Information is presented in a concise and very compact manner	🟢	Fits comfortably within the one-page budget; gate and tier items are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the rendered text.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing assumes a proactive reader who will load, split doses and run a laboratory panel.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol panel presents a 4-to-12-week loading course with split dosing and a maintenance phase.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring card assumes functional-range laboratory testing, not general-population screening.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Benefit tiers carry the ER’s narrow scope (exercise capacity high; cognition confined to older adults with below-normal scores).
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging” in the document.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial route-of-administration or adverse-event phrasing; “dietary supplement”, “doses”, “with food” are formal register.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings verbatim: Protocol (line 446), Time to effect (488), Benefits (532), Risk & Side Effects (596), Monitoring (613), Qualitative Assessment (747), Contraindications (555), Key Interactions (570), Marker/Target/Why (617–619), tier labels High/Medium/Low/Speculative.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; marker_#* and qualitative_item# expanded to 8 and 6 concrete rows respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against [qrs_template] shows head, styles, website= spans and footer byte-identical; only variable regions differ.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section required empty-state carry-over; absent risk tiers are governed by 13.5, which mandates display:none rather than empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels verbatim from ER bold labels: “Standard loading regimen”, “Maintenance regimen”, “Single versus split dosing” (ER 277, 279, 284).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented or paraphrased labels; Monitoring “Why” cells reproduce the ER’s “Why Measure It?” column verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present in the body; ER tier emoji and the ⚠️/⭕️ benefit markers are stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content volume is within the single-A4 budget; ER bullets are condensed rather than carried in full.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment opens on line 2, directly after <!doctype html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by “—” at lines 3 and 13; the preamble text sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not echoed anywhere on the sheet.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration is quoted, which its colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: beta_alanine_2026-0914-0003_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.22, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0922-1610.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Beta-Alanine for Health & Longevity - Quick Reference Sheet”, with & entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Beta-Alanine for Health & Longevity”, matching ER canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/22/2026, matching qrs_creation_date 2026-0922.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only title and the template subline; the ER “Also known as” line is correctly absent.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Beta-alanine is a dietary supplement, an amino acid the body does not use to build proteins, taken to raise stores of carnosine”, naming kind and purpose before any verdict.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER Conclusion lines 368–372: mechanism, best-supported effect, tolerability.
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words, at the limit.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a distinct ER Conclusion passage (368, 370, 372) plus ER 318 for “dietary supplement”.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “buffers acid” rendered as “soaks up acid” and carnosine explained inline.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes or statistics; “more than a hundred human studies” is the ER’s own count, not a result.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from ER “Populations who should avoid Beta-Alanine” (ER 254–260).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER populations represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Five <li> elements inside the [stop_items] span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing em-dash clauses stripped from all five items (e.g., “— no clinical evidence…”, “— amino-acid handling is altered and untested at these stages”).
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Parentheticals preserved and trimmed: “(Child-Pugh Class C)”, “(eGFR under 30 mL/min/1.73 m²)”; thresholds intact.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER Key Interactions & Contraindications uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	N/A	Section is not left empty; ER names five populations that should avoid beta-alanine.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not left empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from ER “Key Interactions & Contraindications” bullets (ER 244–252).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine ER interactions present; no overlap with the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements inside the [caution_items] span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Reduced to “agent: verdict” form; mechanistic rationale and mitigation sentences dropped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved: metformin/glipizide/insulin glargine/semaglutide; methotrexate/isotretinoin/high-dose acetaminophen/alcohol; cetirizine/loratadine.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER Key Interactions & Contraindications uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	N/A	Section is not left empty; ER names nine interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not left empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Drawn from ER Therapeutic Protocol (ER 277–290).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Loading, maintenance and split dosing are the three load-bearing implementation decisions in the ER protocol.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Therapeutic Protocol provides well over three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields carry ER-derived content; action_3_sub adds the ER “Best time of day” dosing-with-food fact (ER 285), also within the Protocol section.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Covers the three aspects named in ER Practical Considerations line 314: performance, cognition, carnosine loading.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High-intensity exercise capacity (High tier) → Cognitive function (Medium tier) → Muscle carnosine loading, reversing the ER’s narrative order to follow benefit magnitude.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER names three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields populated from ER line 314.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information (Practical Considerations, line 314).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Drawn from ER Expected Benefits (ER 147–187).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four tier variables present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to the ER benefit headings; magnitudes and supporting prose omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	ER heading markers “⚠️ Conflicted” and “⭕️ Not Central to Health & Longevity” stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items in the ER; no sub-section is absent.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Drawn from ER Potential Risks & Side Effects (ER 206–230).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four tier variables present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to the ER risk headings; odds ratios and credible intervals omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	Paresthesia and taurine/histidine glosses stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	ER records no Medium and no Low risk (ER 220–225); both spans carry style=”display: none” and no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Drawn from ER Monitoring Protocol & Defining Success (ER 334–343).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers listed with matching targets: ALT, AST, fasting glucose, HbA1c, fasting insulin, eGFR, hs-CRP, muscle carnosine.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with the ER cadence from line 332, including the 4-and-12-week glucose review under glucose-lowering medication.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from ER Monitoring Protocol & Defining Success qualitative list (ER 347–352).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers listed in ER order.

Issues 22/09/2026 16:38

Pass rate 100.00%. No issues found.

Issues 22/09/2026 16:31

1. 13.3 / 13.4 — Added parenthetical gloss in risks: [risks_high] at line 600 reads “Paresthesia (skin tingling); small increase in alanine aminotransferase”; the parenthetical gloss is an explanation absent from the ER heading and must be stripped under the Risks section’s no-parentheses rule.

Fixes 22/09/2026 16:31

1. 13.3 / 13.4 — Stripped parenthetical gloss in risks: Changed [risks_high] from “Paresthesia (skin tingling); small increase in alanine aminotransferase” to “Paresthesia; small increase in alanine aminotransferase”, removing the added parenthetical explanation.

Issues 22/09/2026 16:26

1. 9.2 — Two ER interactions omitted: The Key Interactions gate lists 7 of the 9 interaction bullets in the ER’s Key Interactions & Contraindications section; “Antihistamines (cetirizine, loratadine): no interaction, but no benefit either” (ER line 249) and “L-histidine co-supplementation: no interaction of consequence” (ER line 252) are missing, although comparable no-concern bullets (sodium bicarbonate, creatine monohydrate) were carried over.

Fixes 22/09/2026 16:26

1. 9.2 — Missing interactions added: Added the two omitted ER interaction bullets to the Key Interactions gate — “Antihistamines (cetirizine, loratadine): no interaction, no benefit either” and “L-histidine co-supplementation: no interaction of consequence” — bringing the gate to all 9 ER interaction items.

Issues 22/09/2026 16:21

1. 9.2 — Creatine interaction omitted: The ER’s “Creatine monohydrate: no safety concern; additive” interaction (ER line 246) is absent from the Key Interactions gate, even though the parallel “Sodium bicarbonate: no safety concern, additive by design” bullet was carried over.

Fixes 22/09/2026 16:21

1. 9.2 — Creatine interaction added: Added <li>Creatine monohydrate: no safety concern, additive</li> to the Key Interactions gate, alongside the existing sodium bicarbonate item, restoring the ER interaction bullet at ER line 246.

Issues 22/09/2026 16:15

1. 1.3 — Side-effect claim overstated: At-A-Glance (lines 437-438) asserts “Temporary skin tingling is the only side effect” without the ER Conclusion’s scoping clause “across more than a hundred human studies”, and the categorical form contradicts the sheet’s own High-tier risk entry for a small ALT increase (line 597).

Fixes 22/09/2026 16:15

1. 1.3 — Side-effect claim overstated: Restored the ER Conclusion’s scoping clause in At-A-Glance, changing “Temporary skin tingling is the only side effect.” to “Across more than a hundred human studies, temporary skin tingling was the only side effect.” (70 words, within the 70-word budget).